Old Web
English
Sign In
Acemap
>
authorDetail
>
Honghao Fang
Honghao Fang
Analysis Group
Medicine
Pediatrics
Cost-effectiveness analysis
Montelukast
Exacerbation
4
Papers
3
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Cost-effectiveness analysis of double low-dose budesonide and low-dose budesonide plus montelukast among pediatric patients with persistent asthma receiving Step 3 treatment in China.
2020
Journal of Medical Economics
Xiaoling Wang
Honghao Fang
Kunling Shen
Tianyi Liu
Jipan Xie
Yuantao Liu
Peibei Wu
Yilin Chen
Jia Zhong
Eric Q. Wu
Wei Zhou
Bin Wu
Show All
Source
Cite
Save
Citations (1)
The cost-effectiveness of low-dose budesonide as a Step 2 treatment for pediatric asthma in China.
2020
Journal of Comparative Effectiveness Research
Xiaoling Wang
Honghao Fang
Kunling Shen
Tianyi Liu
Jipan Xie
Yuantao Liu
Jia Zhong
Eric Q. Wu
Wei Zhou
Bin Wu
Show All
Source
Cite
Save
Citations (0)
Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.
2020
Journal of Managed Care Pharmacy
Zheng-Yi Zhou
Karina Raimundo
Anisha M. Patel
Simeng Han
Yusi Ji
Honghao Fang
Jia Zhong
Keith A. Betts
Arash Mahajerin
Show All
Source
Cite
Save
Citations (2)
Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) and Budget Impact Analysis of Venetoclax Plus Obinutuzumab Sequences for CLL Patients Not Eligible for Full Dose Fludarabine in France
2020
Blood
Honghao Fang
Harinala Ravonimbola
Nisha C Hazra
Zhou Zhou
Beenish S Manzoor
Vincent Levy
Loic Ysebaert
Nathanael Kabore
Kavita Sail
Show All
Source
Cite
Save
Citations (0)
1